Global Short Bowel Syndrome Market: Emerging Market Trends, Size, Share and Growth Analysis

The competitive landscape of the global short bowel syndrome market is quite consolidated with Shire Plc. holding about 50% share in the overall market in 2015. Transparency Market Research states that strategic acquisitions have strengthened the company’s foothold in the market over the past few years. In the coming years, Shire is expected to focus on delivering innovating therapies with a special focus on gastrointestinal diseases. “Other players will steer emphasis on manufacturing and marketing over-the-counter dietary supplements to garner significant consumer base,” states the lead author of this research report.

Download Exclusive Brochure of This Report :

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13346

GLP-2 Drug Shows Steady Growth during Forecast Period due to Popularity

According to the research report, the global short bowel syndrome (SBS) market is expected to be worth US$2.6 bn by the end of 2024 as compared to be US$312.7 mn in 2016. Between the years of 2016 and 2024, the global market is expected to rise at a CAGR of 30.4%.

On the basis of drug class, the global market is segmented into GLP-2, glutamine, and growth hormone. Of these, the GLP-2 drug is estimated to rise at a CAGR of 36.0% between 2016 and 2024. Sold under the brand name of Gattex in the U.S. and Revestive in Europe, the GLP-2 drug is expected to make a significant contribution to the rising revenue of the global market due to its exclusivity. On the basis of geography, North America is anticipated to lead the global market as it progresses at a CAGR of 32.7% between 2016 and 2024.

High Cost of Parenteral Nutrition Steers Attention toward SBS Drugs

The high cost of parenteral nutrition, which is administered to the patient to allow the intestine to adapt to the changes and to maintain hemostasis, is anticipated drive the global market. The unaffordability of parenteral nutrition has significantly spiked the demand for short bowel syndrome drugs as they also help in reducing patient’s dependence on parenteral nutrition, as has been observed in the clinical trials. The overall market is also being driven by the growing number of favorable reimbursements offered by the governments across North America. Additionally, assistance offered to patients on Gattex by Shire PLc is also estimated to work in favor of the market’s growth.

Due to the rarity of this disease, the rate of diagnosis has been relatively low for short bowel syndrome. Furthermore, the approved drugs for SBS are not easily available across the globe, which has resulted in a significant pool of unmet clinical needs. In light of these reasons, the global market is expected to find several lucrative opportunities in the coming years. The growing investments and focus of several associations and foundations in raising awareness about short bowel syndrome has played a crucial role in defining the positive trajectory of the global market. Currently, The National Organization for Rare Disorders and its member organizations, such as the Association of Gastrointestinal Motility Disorders, Inc., the Oley Foundation, the SBS Cure Project, and the Short Bowel Syndrome Foundation, Inc. are raising awareness about the diseases amongst people. Drug manufacturers are also initiating awareness programs to offer assistance to patients and earn high revenues.

Adverse Side Effects of SBS Drugs to Restrain Market Growth

The key drawback for the global short bowel syndrome market is the side-effect of taking short bowel syndrome drugs. The drugs approved for treating SBS are associated with a wide range of side effects that can lead to several health complications. For instance, the commonly seen effects of Revestive or Gattex are nausea, abdominal pain, cold, flu, and headache among others. These medicines can also lead to complications pertaining to blockage of the bowel, polyps in the colon, abnormal cell growth resulting in cancer, and inflammation or blockage of gallbladder or pancreas. The market is also likely to be affected by the high mortality rate associated with SBS and non-availability of approved drugs, especially in the developing economies.

This review is based on Transparency Market Research report, titled “Short Bowel Syndrome Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024.”

Browse Global Strategic Business Report:

http://www.transparencymarketresearch.com/short-bowel-syndrome-market.html

The Short Bowel Syndrome Market has been segmented as follows:

Short Bowel Syndrome Market, by Drug Class, Revenue (US$ Mn) 2014-2024
GLP-2
Growth Hormone
Glutamine
Others

Short Bowel Syndrome Market Revenue, by Geography (US$ Mn), 2014-2024
North America
U.S.
Canada
Europe
U.K.
Germany
Spain
France
Italy
Rest of Europe
Rest of the World

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.